Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2'-deoxyadenosine (cladribine) in human lymphocytes

M. Sasvári, T. Spasokoukotskaja, Melinda Szóke, Z. Csapó, Ágnes Turi, Ildikó Szántó, Staffan Eriksson, M. Staub

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Deoxycytidine kinase (dCK, EC.2.7.1.74), a key enzyme in intracellular metabolism of many antileukemic drugs, was shown to be activated during treatment of lymphocytes by 2-chloro-2'-deoxyadenosine (Cl-dAdo, cladribine), a potent inhibitor of DNA synthesis. While 5-[3H]-thymidine (TdR) incorporation into DNA was decreased by 80-90%, dCK activity was doubled as a consequence of incubating the cells with 1 μM 2-chloro-2'-deoxyadenosine. Thymidine kinase (dTK, EC.2.7.1.21) activity was slightly decreased under the same conditions, similarly to 5-[3H]-thymidine incorporation. dCK activation could not be prevented by cycloheximide, and neither the amount of dCK protein nor its mRNA level was increased after 2-chloro-2'-deoxyadenosine treatment. These results suggest a post-translational activation of dCK protein during inhibition of DNA synthesis. Copyright (C) 1998 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)1175-1179
Number of pages5
JournalBiochemical Pharmacology
Volume56
Issue number9
DOIs
Publication statusPublished - Nov 1 1998

Fingerprint

Deoxycytidine Kinase
Cladribine
Lymphocytes
Chemical activation
DNA
Thymidine
Nucleic Acid Synthesis Inhibitors
Thymidine Kinase
Cycloheximide
Metabolism
Proteins
Messenger RNA
Enzymes
Pharmaceutical Preparations

Keywords

  • 2-chloro-2'-deoxyadenosine
  • Cladribine
  • Deoxycytidine kinase
  • Human
  • Lymphocyte
  • Thymidine kinase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2'-deoxyadenosine (cladribine) in human lymphocytes. / Sasvári, M.; Spasokoukotskaja, T.; Szóke, Melinda; Csapó, Z.; Turi, Ágnes; Szántó, Ildikó; Eriksson, Staffan; Staub, M.

In: Biochemical Pharmacology, Vol. 56, No. 9, 01.11.1998, p. 1175-1179.

Research output: Contribution to journalArticle

@article{999431b980ea419995dc16eff61434ed,
title = "Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2'-deoxyadenosine (cladribine) in human lymphocytes",
abstract = "Deoxycytidine kinase (dCK, EC.2.7.1.74), a key enzyme in intracellular metabolism of many antileukemic drugs, was shown to be activated during treatment of lymphocytes by 2-chloro-2'-deoxyadenosine (Cl-dAdo, cladribine), a potent inhibitor of DNA synthesis. While 5-[3H]-thymidine (TdR) incorporation into DNA was decreased by 80-90{\%}, dCK activity was doubled as a consequence of incubating the cells with 1 μM 2-chloro-2'-deoxyadenosine. Thymidine kinase (dTK, EC.2.7.1.21) activity was slightly decreased under the same conditions, similarly to 5-[3H]-thymidine incorporation. dCK activation could not be prevented by cycloheximide, and neither the amount of dCK protein nor its mRNA level was increased after 2-chloro-2'-deoxyadenosine treatment. These results suggest a post-translational activation of dCK protein during inhibition of DNA synthesis. Copyright (C) 1998 Elsevier Science Inc.",
keywords = "2-chloro-2'-deoxyadenosine, Cladribine, Deoxycytidine kinase, Human, Lymphocyte, Thymidine kinase",
author = "M. Sasv{\'a}ri and T. Spasokoukotskaja and Melinda Sz{\'o}ke and Z. Csap{\'o} and {\'A}gnes Turi and Ildik{\'o} Sz{\'a}nt{\'o} and Staffan Eriksson and M. Staub",
year = "1998",
month = "11",
day = "1",
doi = "10.1016/S0006-2952(98)00108-7",
language = "English",
volume = "56",
pages = "1175--1179",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2'-deoxyadenosine (cladribine) in human lymphocytes

AU - Sasvári, M.

AU - Spasokoukotskaja, T.

AU - Szóke, Melinda

AU - Csapó, Z.

AU - Turi, Ágnes

AU - Szántó, Ildikó

AU - Eriksson, Staffan

AU - Staub, M.

PY - 1998/11/1

Y1 - 1998/11/1

N2 - Deoxycytidine kinase (dCK, EC.2.7.1.74), a key enzyme in intracellular metabolism of many antileukemic drugs, was shown to be activated during treatment of lymphocytes by 2-chloro-2'-deoxyadenosine (Cl-dAdo, cladribine), a potent inhibitor of DNA synthesis. While 5-[3H]-thymidine (TdR) incorporation into DNA was decreased by 80-90%, dCK activity was doubled as a consequence of incubating the cells with 1 μM 2-chloro-2'-deoxyadenosine. Thymidine kinase (dTK, EC.2.7.1.21) activity was slightly decreased under the same conditions, similarly to 5-[3H]-thymidine incorporation. dCK activation could not be prevented by cycloheximide, and neither the amount of dCK protein nor its mRNA level was increased after 2-chloro-2'-deoxyadenosine treatment. These results suggest a post-translational activation of dCK protein during inhibition of DNA synthesis. Copyright (C) 1998 Elsevier Science Inc.

AB - Deoxycytidine kinase (dCK, EC.2.7.1.74), a key enzyme in intracellular metabolism of many antileukemic drugs, was shown to be activated during treatment of lymphocytes by 2-chloro-2'-deoxyadenosine (Cl-dAdo, cladribine), a potent inhibitor of DNA synthesis. While 5-[3H]-thymidine (TdR) incorporation into DNA was decreased by 80-90%, dCK activity was doubled as a consequence of incubating the cells with 1 μM 2-chloro-2'-deoxyadenosine. Thymidine kinase (dTK, EC.2.7.1.21) activity was slightly decreased under the same conditions, similarly to 5-[3H]-thymidine incorporation. dCK activation could not be prevented by cycloheximide, and neither the amount of dCK protein nor its mRNA level was increased after 2-chloro-2'-deoxyadenosine treatment. These results suggest a post-translational activation of dCK protein during inhibition of DNA synthesis. Copyright (C) 1998 Elsevier Science Inc.

KW - 2-chloro-2'-deoxyadenosine

KW - Cladribine

KW - Deoxycytidine kinase

KW - Human

KW - Lymphocyte

KW - Thymidine kinase

UR - http://www.scopus.com/inward/record.url?scp=0344973660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344973660&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(98)00108-7

DO - 10.1016/S0006-2952(98)00108-7

M3 - Article

VL - 56

SP - 1175

EP - 1179

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 9

ER -